Document is current
Any future updates will be listed below
-
Authors
Liu, Stephen V.
Nagasaka, Misako https://orcid.org/0000-0001-5308-615X
Atz, Judith
Solca, Flavio https://orcid.org/0000-0001-8756-2046
Müllauer, Leonhard
-
Funding
Funding for this research was provided by:
Boehringer Ingelheim
- License Information
-
More Information
Article History
Received: 29 January 2024
Revised: 6 December 2024
Accepted: 16 January 2025
First Online: 14 April 2025
Competing interests
: S.V.L reports research funding from Abbvie, Alkermes, Elevation Oncology, Genentech, Gilead, Merck, Merus, Nuvalent, RAPT, Turning Point Therapeutics; has consultancy roles with AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Catalyst, Daiichi Sankyo, Eisai, Elevation Oncology, Genentech/Roche, Gilead, Guardant Health, Janssen, Jazz Pharmaceuticals, Merck/MSD, Merus, Mirati, Novartis, Pfizer, Regeneron, Sanofi, Takeda, Turning Point Therapeutics. M.N reports consulting fees from Caris Life Sciences; honoraria from AstraZeneca, Daiichi Sankyo, Novartis, Lilly, Pfizer, EMD Serono, Genentech; travel support from AnHeart Therapeutics; and is a speaker for Mirati, Takeda, Janssen, Blueprint Medicine. J.A. and F.S. report employment with Boehringer Ingelheim. L.M. reports no conflicts of interest.
